We are live on ! Find out more
FBLG icon

FibroBiologics

63 hedge funds and large institutions have $11.9M invested in FibroBiologics in 2024 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

109% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 11

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

3% more funds holding

Funds holding: 6163 (+2)

0.08% more ownership

Funds ownership: 0.78%0.85% (+0.08%)

29% less capital invested

Capital invested by funds: $16.8M → $11.9M (-$4.95M)

Holders
63
Holders Change
+2
Holders Change %
+3.28%
% of All Funds
0.83%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
7
Increased
23
Reduced
11
Closed
4
Calls
Puts
Net Calls
Net Calls Change

FBLG Hedge Fund Activity: Q4 2024 in Review

63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in FibroBiologics (FBLG) for Q4 2024, worth a combined $11.9M — down 29% from $16.8M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new FBLG positions and 4 closed out — a net gain of 3 holders — while 23 added to existing stakes and 11 trimmed.

The largest buyer was Vanguard Group, adding an estimated $377K. The largest seller was Symphony Financial, exiting entirely with an estimated $75.8K sold.

  • 63 institutional investors held FibroBiologics (FBLG) as of Q4 2024, up from 61 in Q3 2024.
  • Funds reported $11.9M of FibroBiologics stock for Q4 2024, down 29% quarter-over-quarter.
  • 7 funds opened new FibroBiologics positions in Q4 2024 and 4 closed out, a net change of +3 holders.
  • The largest FibroBiologics buyer in Q4 2024 was Vanguard Group, an estimated $377K added.
  • The largest FibroBiologics seller in Q4 2024 was Symphony Financial, an estimated $75.8K sold.

Based on aggregated 13F filings for Q4 2024.